Tenaya Therapeutics (NASDAQ:TNYA) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA) in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a $18.00 target price on the stock.

A number of other equities research analysts have also recently issued reports on TNYA. Canaccord Genuity Group reiterated a “buy” rating and set a $16.00 price objective on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Chardan Capital reaffirmed a “buy” rating and set a $18.00 price target on shares of Tenaya Therapeutics in a research report on Wednesday, December 18th. Leerink Partners reissued an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $17.33.

Tenaya Therapeutics Trading Down 0.9 %

NASDAQ:TNYA opened at $1.05 on Monday. The stock has a 50-day simple moving average of $1.97 and a 200 day simple moving average of $2.26. Tenaya Therapeutics has a 52-week low of $0.99 and a 52-week high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.07. As a group, analysts forecast that Tenaya Therapeutics will post -1.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tenaya Therapeutics

A number of institutional investors have recently added to or reduced their stakes in TNYA. abrdn plc lifted its stake in shares of Tenaya Therapeutics by 9.1% in the 4th quarter. abrdn plc now owns 600,700 shares of the company’s stock valued at $859,000 after acquiring an additional 50,000 shares during the last quarter. Spire Wealth Management acquired a new position in Tenaya Therapeutics in the 4th quarter worth about $53,000. Atticus Wealth Management LLC raised its position in Tenaya Therapeutics by 56.3% in the fourth quarter. Atticus Wealth Management LLC now owns 47,762 shares of the company’s stock valued at $68,000 after purchasing an additional 17,199 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Tenaya Therapeutics by 61.9% during the fourth quarter. SG Americas Securities LLC now owns 41,270 shares of the company’s stock valued at $59,000 after purchasing an additional 15,777 shares in the last quarter. Finally, Synovus Financial Corp bought a new stake in shares of Tenaya Therapeutics during the third quarter worth about $28,000. 90.54% of the stock is currently owned by institutional investors and hedge funds.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.